As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger

US Filing Expected Shortly

 
• By Andrew McConaghie

Sanofi and its partner Sobi believe they have the future “Factor VIII of choice” t could also challenge the dominance of Roche’s Hemlibra.

Sanofi_Berlin
Sanofi has made rare blood disorders one of its targeted key growth drivers. • Source: Shutterstock

More from Business

More from Scrip